Precision medicine: Transforming treatment strategies for noncommunicable diseases

The global burden of communicable diseases, such as influenza, acquired immunodeficiency syndrome, hepatitis, malaria, polio, tuberculosis, and more recently, coronavirus disease, has been a major cause of illness and death. These diseases are a key concern in global health because they spread from person to person in various ways. They can easily cross borders and threaten the lives of millions worldwide. Thanks to improvements in sanitation, vaccines, antibiotics, and public health measures, deaths and illness from communicable diseases have dropped significantly in many areas. However, modern lifestyles have contributed to a rise in noncommunicable diseases (NCDs). Factors such as sedentary behavior, unhealthy diets, addictions (such as tobacco use and alcohol consumption), environmental issues, and longer life expectancies have played a role in this shift. NCDs include cardiovascular diseases (heart disease, hypertension, and stroke), type 2 diabetes, chronic respiratory diseases (asthma, chronic obstructive pulmonary disease), and neurological and psychiatric disorders (Alzheimer’s and Parkinson’s diseases), as well as cancers. These modern lifestyles have led to four main metabolic or physiological changes: high blood pressure, overweight or obesity, high blood glucose, and high cholesterol. The “invisible epidemic” of NCDs is the leading cause of death worldwide.[1] NCDs account for about 75% of all deaths not related to pandemics globally. In 2021, at least 43 million people died from NCDs, making up roughly three-quarters of global deaths (World Health organization [WHO]–NCDs Fact Sheet, 2025). That same year, around 18 million NCD-related deaths occurred before age 70 years, with 82% of these premature deaths happening in low- and middle-income countries (WHO-Universal Health CoverageDashboard, 2025). Cardiovascular diseases are responsible for about 19 million deaths worldwide. As a result, health systems have changed from focusing on treating acute, infectious diseases to managing chronic, long-term conditions. This change emphasizes prevention, early detection, long-term care, and personalized treatment instead of short-term cures. Therefore, strategies such as precision medicine, molecular medicine, lifestyle changes, and chronic disease management are becoming more important in modern health care. Preventing NCDs involves reducing risk factors and conducting early screenings, while treatment focuses on long-term management rather than finding a cure. Precision medicine, often called personalized medicine, is highly relevant in NCDs because these conditions are chronic and multifactorial. They show wide variation in risk, progression, and treatment response among individuals. Precision medicine focuses on health care where treatment and prevention are tailored to each person, rather than using a one-size-fits-all model. In cancer treatment, precision medicine has been effective and has progressed quickly because cancers are driven by specific genetic and molecular changes that can be targeted directly. Precision medicine is not only about cancer anymore. It is increasingly influencing how we prevent, diagnose, and treat all types of NCDs by matching therapy to genetic, molecular, and lifestyle differences among patients. Precision approaches use genomic data and biomarker profiles to identify individuals at high risk of NCDs. Genetic risk scores and “omics” technologies, which include genomics, proteomics, and metabolomics, assist in deep phenotyping. This helps define disease subtypes and individual risk, allowing for tailored preventive measures.[2] One of the earliest and most successful examples of precision medicine in breast cancer involves biomarker testing for hormone receptors, specifically estrogen and progesterone receptors, and HER2, which stands for human epidermal growth factor receptor 2. Hormone receptor-positive tumors are treated with endocrine therapies such as tamoxifen or aromatase inhibitors that block hormone signaling. In contrast, HER2-positive tumors benefit from therapies that specifically target HER2, such as trastuzumab and pertuzumab, which inhibit HER2 signaling and improve survival.[3] In cardiovascular diseases, precision medicine guides drug selection and dosing through pharmacogenomics. Like, it tailors warfarin or clopidogrel therapy based on CYP2C9 and VKORC1 gene variants. It also helps identify individuals with inherited conditions like familial hypercholesterolemia early on. Biomarker-guided treatment strategies, such as using miRNAs or metabolic profiles, enable earlier detection and personalized intervention in myocardial infarction and heart failure.[4] In diabetes, precision medicine distinguishes monogenic diabetes from type 1 or type 2 diabetes. This distinction allows for appropriate therapy selection and supports personalized treatment plans using genetic, metabolic, and continuous glucose-monitoring data. In respiratory diseases like asthma, biomarker-based classification, including eosinophils and immunoglobulin E, allows for targeted biologic therapies instead of generalized treatment. In neurological and psychiatric disorders, genetic profiling can predict drug response and side effects. This approach reduces trial-and-error prescribing. Overall, precision medicine in NCDs improves treatment effectiveness, reduces adverse drug reactions, enables early intervention, and supports long-term disease management. Beyond genetics, precision medicine uses clinical records, imaging, wearable devices, and digital health indicators to evaluate patients and change treatment regimens in real time. This promotes patient-centered, dynamic care.[5] Molecular and precision approaches are transforming NCD management by shifting treatment from a generalized, symptom-focused model to individualised care. The molecular transformation employs genomic, proteomic, metabolomic, and other “omics” technology to study illness biologically and molecularly. This allows customized prevention, diagnosis, and treatment. Classifying illnesses by clinical appearance and broad risk factors was traditional NCD treatment. Molecular transformation deciphers genetic susceptibility, gene–environment interactions, epigenetic alterations, and molecular markers, which influence illness onset and progression. The integration of genomic, transcriptomic, proteomic, and metabolomic analyses provides deeper insight into the biological mechanisms underlying NCDs and supports personalized treatment approaches. Genome-wide analysis and genetic risk scores may predict disease susceptibility, notably in cardiovascular illnesses, type 2 diabetes, and malignancies, where common variations increase risk before symptoms manifest. Deep phenotyping uses genomic and clinical data to stratify patients into risk categories for targeted prevention.[6] Proteins, metabolites, and microRNAs are increasingly employed to diagnose NCDs earlier, track their course, and assess therapy responses. This is a major shift from nonspecific clinical signs to biomarker-guided models that represent disease biology.[6] Precision medicine also targets particular biological targets for treatment. CHALLENGES IN IMPLEMENTATION OF PRECISION MEDICINE IN NONCOMMUNICABLE DISEASES Precision medicine may improve NCD outcomes by tailoring prevention and therapy to molecular profiles, but its application in NCD management is difficult. These include workforce knowledge gaps, infrastructure and data restrictions, high costs, ethical and regulatory problems, equality challenges, and the lack of systematic evidence and implementation frameworks to translate it into normal treatment. Many healthcare professionals lack the expertise to assess genetic and molecular data. They have trouble using biomarkers in clinical choices and precision therapies. This makes evaluating complicated test findings and implementing them challenging. Gaps hinder or prohibit normal care integration. Multidisciplinary teams, genetic sequencing facilities, and bioinformatics pipelines are also needed for precision medicine. Many health systems, particularly low-resource ones, lack these skills. Poorly defined staff responsibilities, understaffing, and inefficient processes limit implementation.[7] High costs of genetic or molecular testing, targeted therapies, and the related clinical support can burden patients and health systems. Out-of-pocket expenses, lack of insurance coverage, and unclear pathways for ongoing funding limit fair access. There is often no clear financing plan to support routine use beyond pilot programs.[7] Precision medicine produces large amounts of complex data, including genomic, proteomic, and metabolomic information. This data must be combined with clinical records. Storing, analyzing, and interpreting these data need bioinformatics tools and expertise, which are still evolving. Without solid systems to turn raw data into practical insights, clinical usefulness is restricted. The use of genetic and molecular information raises ethical issues about informed consent, privacy, discrimination, and data security. Patients may worry about the misuse of their genetic data by insurers or employers. Furthermore, regulations vary widely across regions, making implementation more difficult.[8] FUTURE DIRECTIONS OF PRECISION MEDICINE IN NONCOMMUNICABLE DISEASE TREATMENT Precision medicine will swiftly change NCD prevention, diagnosis, and treatment. Genomic, multiomics, real-world data, artificial intelligence (AI), and digital health advances will be combined. This will advance predictive, tailored, and preventative health care. Precision medicine will progressively use genomes, transcriptomics, proteomics, metabolomics, and epigenomics to elucidate NCDs’ intricate biological pathways. This precise molecular data will enhance risk prediction, subtype categorization, and targeted medication selection for personalized care. Biomarkers for disease risk, progression, and therapeutic response will be validated and used clinically as research continues. This biomarker will help clinicians discover NCDs sooner and choose the best therapy for each patient.[9] Precision medicine will move from treating to predicting and preventing illnesses. Genetic risk scores, behavioral risk profiles, and wearable sensors will enable earlier and more focused therapies, reducing long-term health difficulties and expenditures. Analysis of big, heterogeneous datasets will need AI and machine learning. They will expedite biomarker discovery by finding patterns humans overlook. These techniques enhance diagnosis, risk assessment, therapy selection, and real-time monitoring. Precision medicine will become more efficient and scalable. Genomic data, electronic health records, mobile health applications, and telemedicine platforms will provide flexible, patient-specific treatment. Remote monitoring and tailored therapy modifications will also be possible. Global research networks are needed to provide inclusive datasets and universal interventions. Precision medicine offers a new way to manage NCDs by shifting from a general, symptom-based approach to personalized, mechanism-based care. It combines genomic, proteomic, metabolomic, and molecular biomarker data with clinical, environmental, and lifestyle information. This approach allows for early risk prediction, focused therapy, personalized prevention, and ongoing disease monitoring. Although there are still challenges such as infrastructure issues, high costs, data complexity, workforce readiness, and fairness concerns, advances in multiomics technologies, AI, digital health, and implementation science are making broader use possible. In the end, precision medicine in NCDs aims to improve patient outcomes, increase treatment effectiveness, lessen side effects, and use healthcare resources more efficiently. This signals a new era in managing chronic diseases that focuses on prediction, prevention, and personalization.